Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3380)	5/31/2007 11:30:08 AM
From: Jibacoa	Read Replies (2) \| Respond to of 7424

PCYC Was up 15% Its CEO is making a presentation today at the 2007 Friedman Billings Ramsey Growth Conference on The Grand Hyatt in New York City. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (3380)	6/5/2007 1:51:54 PM
From: tuck	Respond to of 7424

ENCY again, 17% now, as PDUFA date gets nearer. Volume is pretty large, and speculation that the third time will be the charm is apparently the driver, if not an outright leak of such news. I'll take either one. Don't own shares anymore, but my Mom does, and I am still short a fair number of puts. Option IV's are just huge; this event is pretty binary. There is floor, given the approvals in other countries. An alternate explanation would be a delay or rejection of Gilead's Ambrisentan, which would compete with ENCY's Thelin in the PAH market. Some say it is best in class. Odds seem low for this explanation. If one can't play the volatility by some fancy option strategy that is basically price neutral, best to stand aside, unless one believes strongly one way or the other about Thelin's chances. And sell the approval news if it comes, as the Ambrisentan PDUFA date is only a couple of days after Thelin's. Cheers, Tuck